If you spend any time in the recovery and rehabilitation corner of the optimisation world, you will run into the same pairing. BPC-157 and TB-500, run together for tendon, ligament, and soft tissue recovery. The combination has become standard in a lot of protocols, but the reasoning behind it is less commonly explained. Here is a careful look at what each peptide does, why they get paired, and how to think about whether the stack makes sense for you.
The two peptides, separately
BPC-157 is a 15-amino-acid peptide originally derived from a protein in gastric juice. The bulk of its research interest sits in tissue repair, gut healing, and reduction of inflammation. Animal studies suggest it supports angiogenesis (the formation of new blood vessels into healing tissue), modulates growth factors, and accelerates several types of tendon and ligament recovery. Human evidence is largely anecdotal, with a growing base of clinician case reports.
TB-500, also called thymosin beta-4, is a peptide naturally produced by the thymus and many other tissues. Its role in the body is connected to cell migration, particularly the migration of stem cells and inflammatory cells into areas of injury. It appears to promote actin filament formation, which is part of how cells reshape and repair themselves. Animal data points to faster wound healing, improved cardiac repair after damage, and accelerated muscle and tendon recovery.
Why they get paired
The case for stacking the two is mechanistic. They work through different but complementary pathways:
- BPC-157 may support the local tissue response. Blood vessel formation, growth factor signalling, and the resolution of local inflammation.
- TB-500 may support cell migration into the injury site. The stem cells, fibroblasts and other cells that actually do the repair work get to the right place faster.
In theory, the two peptides hit different parts of the recovery cascade. Together, they may produce a more complete environment for healing than either does alone.
What the evidence actually supports
Three honest caveats:
- The combination has not been studied in a rigorous human trial. Most of the case for the stack comes from animal work on the individual peptides and from clinician experience using them together.
- The mechanistic case is reasonable, but mechanistic plausibility does not equal clinical proof. A lot of combinations that look good on paper do not produce additive effects in practice.
- Most of the strongest anecdotes involve significant soft tissue injuries. The stack appears most useful in the context of an actual injury or surgical recovery, not as a general optimisation tool.
When stacking makes sense
Based on what we see with clients, the stack tends to be appropriate when:
- The injury is significant and slow. Chronic tendinopathy, post-surgical recovery, or an injury that has stalled despite physical therapy.
- The client is committed to the rest of the protocol. Physical therapy, training around the injury, sleep, protein, and load management are not optional. The peptides modulate a system that the rest of the protocol is building.
- The cycle is well-defined. Four to eight weeks, with clear measurable outcomes (pain, range of motion, ability to return to specific activities).
- The source is high quality and the dosing is reasonable. Grey market product or aggressive dosing tends to produce side effects without proportionate benefit.
When stacking does not make sense
Equally important. The stack is not the right answer when:
- The goal is generalised wellness rather than a specific recovery target. Stacking two recovery peptides for the sake of "more recovery" is not a clear use case.
- The injury is minor or new. A fresh ankle sprain or routine post-training soreness does not need a stacked protocol. Rest, sleep and ordinary recovery practices are almost always enough.
- The client is in competitive sport. Both peptides are on or near the prohibited list. The risk to a career or to integrity is not worth the marginal benefit.
- The underlying issue is mechanical, not biological. Some injuries do not heal because the joint or tissue is loaded wrong. No peptide fixes a loading problem.
How to think about dosing
In the protocols we design, the typical pattern is:
- BPC-157 dosed daily through the cycle, often in a single subcutaneous injection near the area of interest where appropriate.
- TB-500 dosed less frequently. A loading phase of two to four weeks at a higher frequency, followed by a maintenance phase or a planned wind-down.
- Both run on the same calendar to keep the protocol simple to follow.
The specific dose, frequency, and route depend on the injury, the client's history, and the goals. There is no one-size-fits-all answer, which is part of why a stacked protocol should not be self-designed from a forum thread.
The Reset takeaway
BPC-157 and TB-500 are the most commonly stacked recovery peptides for reasons that make mechanistic sense, even if the rigorous human evidence is still catching up. Used appropriately, the stack may support recovery from significant soft tissue injuries when the rest of the protocol (physical therapy, training, sleep, nutrition) is well-managed. Used poorly, it is an expensive way to take peptides without a clear goal. If you are considering the stack for a specific recovery target, message us. The right protocol depends on what you are actually trying to recover from.
This article is for educational purposes only and does not constitute medical advice. Both peptides discussed are not approved for human use by major regulators and are restricted in competitive sport. Always consult a qualified healthcare provider before considering any peptide protocol.